<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Trastuzumab</title>
	<atom:link href="http://www.tapanray.in/tag/trastuzumab/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Patent Expiry No Longer End of The Road</title>
		<link>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-expiry-no-longer-end-of-the-road</link>
		<comments>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/#comments</comments>
		<pubDate>Sun, 03 Dec 2017 23:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Adalimumab]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[exemptia]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infliximab]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Rituximab]]></category>
		<category><![CDATA[Road]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8600</guid>
		<description><![CDATA[Who says that the phenomenal success of blockbuster drugs is mostly eaten away by  ‘look-alikes’ of the same, immediately after respective patent expiry? It doesn’t seem to be so any longer, not anymore! Several examples will vindicate this emerging trend. &#8230; <a href="http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-expiry-no-longer-end-of-the-road/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Herceptin Biosimilars’ Seriously Questioned</title>
		<link>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilars-seriously-questioned</link>
		<comments>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/#comments</comments>
		<pubDate>Fri, 07 Feb 2014 11:17:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CTRI]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hertaz]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questioned]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[wife]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4969</guid>
		<description><![CDATA[The news struck as an anticlimax, close on the heels of high decibel product launch of ‘Herceptin Biosimilars’ in India, being hyped as the first in the world, bringing much needed relief to many diagnosed breast cancer patients for their &#8230; <a href="http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilars-seriously-questioned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Horizon: Cloud, Rainbow And Smear</title>
		<link>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-horizon-cloud-rainbow-and-smear</link>
		<comments>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/#comments</comments>
		<pubDate>Mon, 09 Dec 2013 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cloudy]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monster]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sky]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[taint]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4400</guid>
		<description><![CDATA[Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend &#8230; <a href="http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Ghost Keeps Haunting: NCD Dogs Cancer in &#8216;Compulsory License&#8217; Debate of India</title>
		<link>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india</link>
		<comments>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/#comments</comments>
		<pubDate>Mon, 11 Mar 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Citizens']]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[collective]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[dogs]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[ghost]]></category>
		<category><![CDATA[haunting]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[keeps]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[leukemia]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[protein]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treat]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[used]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2037</guid>
		<description><![CDATA[In November 2012, as a part of the ‘Campaign for Affordable Trastuzumab’ for the treatment of breast cancer, a citizens’ collective, reportedly sent an ‘Open Letter’ signed by around 200 cancer survivors, women’s groups, human rights and health rights campaigns &#8230; <a href="http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ghost-keeps-haunting-ncd-dogs-cancer-in-compulsory-license-debate-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Government Ups the Ante for More Compulsory Licenses in India</title>
		<link>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=government-ups-the-ante-for-more-compulsory-licenses-in-india</link>
		<comments>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/#comments</comments>
		<pubDate>Mon, 21 Jan 2013 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Dasatinib]]></category>
		<category><![CDATA[deficiencies]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Ixabepilone]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[skewed]]></category>
		<category><![CDATA[the ante]]></category>
		<category><![CDATA[third]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[uncertainty]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1442</guid>
		<description><![CDATA[On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly &#8230; <a href="http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/government-ups-the-ante-for-more-compulsory-licenses-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
